Wall Street Zen Downgrades Structure Therapeutics (NASDAQ:GPCR) to Strong Sell

Key Points

• Wall Street Zen downgraded Structure Therapeutics (NASDAQ: GPCR) from “sell” to “strong sell,” despite the broader analyst consensus remaining “Moderate Buy” with an average price target of $110.91.
• GPCR opened at $27.67, well below its 50-day and 200-day moving averages of $44.67 and $45.79, respectively, and has fallen near its 1-year low of $25.59.
• The company missed quarterly earnings expectations, reporting a loss of $0.49 per share versus the estimated $0.39 loss; analysts expect a full-year loss of $1.87 per share.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued on Saturday, Wall Street Zen reports.

Several other brokerages have also recently issued reports on GPCR. Canaccord Genuity Group set a $111.00 price objective on Structure Therapeutics in a report on Friday, August 7th. Weiss Ratings lowered Structure Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, September 18th. Citizens Jmp reiterated a "market outperform" rating and set a $110.00 price target on shares of Structure Therapeutics in a research report on Wednesday, September 9th. HC Wainwright restated a "buy" rating on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Structure Therapeutics has an average rating of "Moderate Buy" and an average price target of $110.91.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $27.67 on Friday. The company's fifty day moving average price is $44.67 and its 200-day moving average price is $45.79. Structure Therapeutics has a 1-year low of $25.59 and a 1-year high of $94.90. The firm has a market capitalization of $1.93 billion, a P/E ratio of -27.67 and a beta of -1.30.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). Equities analysts anticipate that Structure Therapeutics will post -1.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. IFP Advisors Inc acquired a new stake in shares of Structure Therapeutics in the second quarter valued at about $46,000. Squarepoint Ops LLC raised its position in shares of Structure Therapeutics by 454.5% during the 2nd quarter. Squarepoint Ops LLC now owns 125,575 shares of the company's stock worth $6,740,000 after purchasing an additional 102,929 shares during the last quarter. Seven Fleet Capital Management LP raised its position in shares of Structure Therapeutics by 197.8% during the 2nd quarter. Seven Fleet Capital Management LP now owns 26,800 shares of the company's stock worth $1,442,000 after purchasing an additional 17,800 shares during the last quarter. Wellington Management Group LLP lifted its stake in Structure Therapeutics by 1.6% in the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company's stock valued at $396,054,000 after buying an additional 119,146 shares in the last quarter. Finally, Handelsbanken Fonder AB acquired a new stake in Structure Therapeutics in the 2nd quarter worth about $1,041,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs.

Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.